Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive

Tomoichiro Oka; Takeshi Kujiraoka; Mayumi Ito; Tohru Egashira; Sadao Takahashi; M. Nazeem Nanjee; Norman E. Miller; Jari Metso; Vesa M. Olkkonen; Christian Ehnholm; Matti Jauhiainen; Hiroaki Hattori

Journal of Lipid Research (Oct 2000)

Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive

Tomoichiro Oka,
Takeshi Kujiraoka,
Mayumi Ito,
Tohru Egashira,
Sadao Takahashi,
M. Nazeem Nanjee,
Norman E. Miller,
Jari Metso,
Vesa M. Olkkonen,
Christian Ehnholm,
Matti Jauhiainen,
Hiroaki Hattori

Affiliations

Tomoichiro Oka: To whom correspondence should be addressed.; Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
Takeshi Kujiraoka: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
Mayumi Ito: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
Tohru Egashira: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
Sadao Takahashi: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
M. Nazeem Nanjee: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
Norman E. Miller: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
Jari Metso: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
Vesa M. Olkkonen: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
Christian Ehnholm: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
Matti Jauhiainen: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland
Hiroaki Hattori: Research Department, Research and Development Center, BML, Kawagoe, Saitama 350-1101, Japan; Third Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan; Department of Cardiovascular Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London EC1Y6BQ, United Kingdom; Department of Biochemistry, National Public Health Institute, Helsinki, Finland

Journal volume & issue: Vol. 41, no. 10
pp. 1651 – 1657

Abstract

Read online

Plasma phospholipid transfer protein (PLTP) plays an important role in the maintenance of plasma high-density lipoprotein (HDL) content and remodeling of HDL in the circulation. In the present study we have used different fractionation methods to investigate the distribution of PLTP in human plasma. A novel enzyme-linked immunosorbent assay developed during the study allowed for simultaneous assessment of both PLTP mass and activity in the fractions obtained. Size-exclusion chromatography and plasma fractionation by nondenaturing polyacrylamide gel electrophoresis (PAGE) yielded similar results demonstrating that PLTP associates in native plasma with two distinct particle populations, while ultracentrifugation with high salt leads to detachment of PLTP from lipoprotein particles and loss of a majority of its phospholipid transfer activity. Interestingly, analysis of the size-exclusion chromatography fractions demonstrated that PLTP exists in the circulation as an active population that elutes in the position of HDL corresponding to an average molecular mass of 160 ± 40 kDa and an inactive form with an average mass of 520 ± 120 kDa. The inactive fraction containing approximately 70% of the total PLTP protein eluted between HDL and low density lipoprotein (LDL). Thus, the two PLTP pools are associated with different types of lipoprotein particles, suggesting that the PLTP activity in circulation is modulated by the plasma lipoprotein profile and lipid composition.—Oka, T., T. Kujiraoka, M. Ito, T. Egashira, S. Takahashi, M. N. Nanjee, N. E. Miller, J. Metso, V. M. Olkkonen, C. Ehnholm, M. Jauhiainen, and H. Hattori. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J. Lipid Res. 2000. 41: 1651–1657.

Published in Journal of Lipid Research

ISSN: 0022-2275 (Print); 1539-7262 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science: Chemistry: Organic chemistry: Biochemistry
Website: https://www.journals.elsevier.com/journal-of-lipid-research

About the journal

Abstract

Keywords